MedTrace Logo

MR-proADM and CT-proET-1 During ICU Treatment

NCT03651635 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 533

Last updated 2021-06-02

No results posted yet for this study

Summary

This pilot-study will be a prospective, single-centre, observational study including 100 critically ill patients consecutively admitted to the medical intensive care unit (ICU) of the University hospital of Zurich, Switzerland, to assess and validate the use of MR-proADM and the CT-proET1/MR-proADM-ratio as prognostic markers in critically ill patients.

Conditions

  • Acute Phase Biomarkers
  • Medical ICU Admitted Patients

Interventions

DIAGNOSTIC_TEST

Blood sampling for MR-proADM & CT-proET-1

Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM \& CT-proET-1

Sponsors & Collaborators

  • ThermoFisher Scientific Brahms Biomarkers France

    collaborator INDUSTRY

  • University of Zurich

    lead OTHER

Principal Investigators

  • Marco Maggiorini, MD · University Zürich/ University Hospital Zürich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-08
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03651635 on ClinicalTrials.gov